Michael Henry, MD
Ophthalmology · Tucson, AZNPI 1346694163
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,420 of the $4,520 with a category attached, or 75.7%. 21 manufacturers reported payments, led by Seagen Inc. at 24.3% of the total. Reporting peaked in 2022 at $1,689 and has fallen 56.9% since, to $728 in 2025.
Across 105 payments — averaging $43.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$1K
- AbbVie$966
- Glaukos Corporation$480
- Alcon$277
- AstraZeneca$190
- Rxsight Inc$172
- plus $1K from 15 others
Across 63 payments — averaging $3098.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Glaukos Corporation$195K
What the payments were for
- Consulting fees$1,10024%
- Food & beverage$3,42076%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 1 | $1,100 |
| AbbVie(2 entities) | 30 | $966 |
| Glaukos Corporation | 9 | $480 |
| Alcon | 3 | $277 |
| AstraZeneca | 13 | $190 |
| Rxsight Inc | 3 | $172 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $171 |
| Bausch & Lomb Americas Inc. | 8 | $147 |
| Carl Zeiss Meditec USA, Inc. | 1 | $145 |
| Apellis Pharmaceuticals, Inc. | 1 | $120 |
| Lantheus Medical Imaging, Inc. | 6 | $102 |
| Oyster Point Pharma, Inc. | 1 | $97 |
| Tarsus Pharmaceuticals, Inc. | 3 | $97 |
| Johnson & Johnson Vision Care, Inc. | 1 | $91 |
| Amgen | 5 | $87 |
| Novartis | 5 | $72 |
| Sun Pharmaceutical Industries Inc. | 2 | $65 |
| Abbott | 3 | $58 |
| Harrow Eye, LLC | 2 | $50 |
| Eyevance Pharmaceuticals LLC | 1 | $19 |
| Akorn Operating Company LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ADCETRIS$1,100
- DURYSTA$365
- AcrySof$253
- iDose$182
- Humphrey HFA$145
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$134
- iStent$124
- Syfovre$120
How this compares
$4,520 in reported general payments places this provider in the 75th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 457 | $207,847 |
| RestasisCyclosporine | 42 | $47,320 |
| Phospholine IodideEchothiophate Iodide | 14 | $34,813 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 94 | $29,964 |
| CombiganBrimonidine Tartrate/Timolol | 56 | $22,457 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 100 | $19,265 |
| VyzultaLatanoprostene Bunod | 44 | $17,653 |
| RhopressaNetarsudil Mesylate | 41 | $16,904 |
| RocklatanNetarsudil Mesylat/Latanoprost | 28 | $11,367 |
| Travoprost | 70 | $10,088 |
| Prednisolone Acetate | 291 | $9,412 |
| Alphagan PBrimonidine Tartrate | 31 | $8,931 |
| Latanoprost | 903 | $8,401 |
| Tobradex StTobramycin/Dexamethasone | 17 | $5,648 |
| Brimonidine Tartrate | 215 | $5,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $966 | $286,555586 claims |
| AlconSimbrinza | $277 | $29,96494 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $147 | $17,65344 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $19 | $5,64817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Tucson
- Martin WorrallTucson$12K
- Brock BakewellTucson$12K
- Sean GarrityTucson$11K
- Andreas GonzalezTucson$11K
- Lynn PolonskiTucson$9K
- Joseph JulianoTucson$9K
- Ajay SananTucson$8K
- Michael DiesenhouseTucson$7K
- Ovette VillavicencioTucson$6K
- Rachel HuynhTucson$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.